



Learn more on Wednesday, July 6, when Akashi Chief Medical Officer Dr. Diana Escolar chairs a panel on a multiple therapeutic intervention strategy for DMD treatment.

When

Wednesday
July 6, 2016
5:15 - 6:15pm

Where

Osgoode Ballroom
West, Sheraton
Centre Toronto Hotel

This presentation was approved by the Program Committee as an independent activity held in conjunction with the 14th International Congress on Neuromuscular Diseases. This presentation is not sponsored or endorsed by ICNMD 2016.

Multi-pathway Approach to DMD Treatment

Chairperson

Diana Escolar, M.D.
Chief Medical Officer, Akashi Therapeutics, Inc.

Introduction

Antifibrotics:

HT-100 For The Treatment Of DMD

Modulating Calcium Homeostasis:

AT-300 Effects In The mdx Mouse Model Of DMD

A Novel Approach To Building Muscle In DMD:

DT-200, Selective Androgen Receptor Modulator